Log in to your Inderes Free account to see all free content on this page.

Karo Pharma

Be the first to follow this company

Karo Pharma is a biotechnology company. The company owns and commercializes prescription drugs and over-the-counter consumer products sold in pharmacies and retailers as well as through online channels. Through direct sales organizations and distributor networks, the company's products are available globally, but with its core business in Europe. The company is headquartered in Stockholm.

ShowingAll content types

Regulatory press release11/10/2022, 7:00 PM

Karo Pharma Aktiebolag's application for de-listing has been approved

Regulatory press release11/10/2022, 1:00 PM

Karo Pharma Aktiebolag applies for de-listing

Regulatory press release9/26/2022, 6:30 AM

Karo Pharma: Karo Intressenter AB initiates compulsory redemption

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release8/26/2022, 6:00 AM

Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion

Regulatory press release8/16/2022, 12:00 PM

Comment from Karo Pharma Aktiebolag's board of directors regarding the public offer from Karo Intressenter AB

Regulatory press release7/21/2022, 6:00 AM

Karo Pharma: Interim report H1 2022

Regulatory press release4/19/2022, 6:30 AM

Karo Pharma's rights issue fully subscribed

Regulatory press release4/12/2022, 2:00 PM

Karo Pharma publishes the 2021 annual report

Regulatory press release4/1/2022, 11:30 AM

Karo Pharma completes the acquisition of the E45® brand from Reckitt

Regulatory press release3/23/2022, 11:00 AM

Karo Pharma publishes prospectus relating to the rights issue and receives approval to change listing venue to Nasdaq First North Growth Market

Regulatory press release3/16/2022, 7:00 AM

Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.5 billion and announces the terms of the rights issue

Regulatory press release3/10/2022, 1:00 PM

Karo Pharma receives approval to delist the Company's share from Nasdaq Stockholm in connection with the change of listing venue to Nasdaq First North Growth Market

Regulatory press release3/9/2022, 11:00 AM

Karo Pharma applies for delisting of the Company's shares from Nasdaq Stockholm, in connection with the change of listing venue to Nasdaq First North Growth Market

Regulatory press release2/25/2022, 1:00 PM

Karo Pharma: Year-end report 2021

Regulatory press release1/13/2022, 2:30 PM

Karo Pharma completes the acquisition of Sylphar International NV

Regulatory press release12/24/2021, 7:00 AM

Karo Pharma enters into an agreement for the potential acquisition of the E45® brand from Reckitt

Regulatory press release12/15/2021, 7:00 AM

Karo Pharma intends to change listing venue to Nasdaq First North Growth Market during the first half of 2022

Regulatory press release11/22/2021, 11:20 PM

Karo Pharma acquires Sylphar International NV for EUR 290m and intends to carry out a rights issue of approximately EUR 200-250m

Regulatory press release10/28/2021, 6:00 AM

Karo Pharma Quarterly report Q3 2021

Regulatory press release9/7/2021, 6:00 AM

Anna Hale appointed CMO at Karo Pharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.